Martin S. Polinsky

Belatacept and Long-Term Outcomes in Kidney Transplantation

Flavio Vincenti, Lionel Rostaing, J.M. Boria Grinyo et al. · New England Journal of Medicine · 2016 · 759 citations · Full text

Medicine, Nephrology, Pharmacotherapy +14

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

Francesco Paolo Schena, M.D. Pascoe, Josefina Alberú et al. · Transplantation · 2009 · 576 citations

Pharmacy, Nephrology, Pharmacotherapy +17

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

Josefina Alberú, M.D. Pascoe, Josep M. Campistol et al. · Transplantation · 2011 · 222 citations

Medicine, Immunology, Nephrology +17

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Antoine Dürrbach, Sander Florman, María del Carmen Rial et al. · American Journal of Transplantation · 2016 · 155 citations · Full text

Medicine, Nephrology, Pharmacotherapy +16

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

Robert A. Bray, Howard M. Gebel, Robert Townsend et al. · American Journal of Transplantation · 2018 · 131 citations · Full text

Life Sciences, Immunology, Pharmacology +17